What is Lifesci Capital's Forecast for AVDL Q3 Earnings?

Key Points

• Avadel Pharmaceuticals is projected to report earnings of $0.06 per share for Q3 2025, with a year-end estimate of ($0.51) per share.
• Several analysts have rated Avadel Pharmaceuticals with a Strong-Buy rating, and the average price target for the stock is $19.14.
• The company's shares opened at $14.99, reflecting significant growth from a 1-year low of $6.38 and a high of $16.66.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Free Report) - Equities researchers at Lifesci Capital issued their Q3 2025 earnings per share estimates for shares of Avadel Pharmaceuticals in a report released on Wednesday, September 3rd. Lifesci Capital analyst F. Brisebois expects that the company will earn $0.06 per share for the quarter. Lifesci Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Avadel Pharmaceuticals' Q4 2025 earnings at $0.07 EPS, FY2025 earnings at $0.18 EPS and Q1 2026 earnings at $0.08 EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.02 by $0.08. Avadel Pharmaceuticals had a negative return on equity of 3.73% and a negative net margin of 1.32%.The firm had revenue of $68.13 million during the quarter, compared to the consensus estimate of $60.28 million. During the same period in the prior year, the company earned ($0.14) EPS. The firm's revenue was up 64.1% compared to the same quarter last year. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.

Several other research firms also recently commented on AVDL. Wall Street Zen raised Avadel Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Zacks Research upgraded Avadel Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 8th. Wells Fargo & Company upgraded Avadel Pharmaceuticals to a "hold" rating in a report on Wednesday. UBS Group upped their target price on Avadel Pharmaceuticals from $13.00 to $20.00 and gave the company a "buy" rating in a report on Thursday, August 21st. Finally, HC Wainwright upped their target price on Avadel Pharmaceuticals from $24.00 to $36.00 and gave the company a "buy" rating in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $20.86.

Avadel Pharmaceuticals Price Performance

NASDAQ AVDL traded up $0.77 during mid-day trading on Friday, hitting $15.76. The stock had a trading volume of 2,024,679 shares, compared to its average volume of 1,309,064. The firm's 50 day moving average is $12.00 and its 200 day moving average is $9.76. Avadel Pharmaceuticals has a twelve month low of $6.38 and a twelve month high of $16.66. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of -525.33 and a beta of 1.57.

Hedge Funds Weigh In On Avadel Pharmaceuticals

A number of hedge funds have recently modified their holdings of AVDL. Nisa Investment Advisors LLC boosted its holdings in Avadel Pharmaceuticals by 164.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $29,000 after acquiring an additional 2,055 shares during the period. Raymond James Financial Inc. purchased a new position in Avadel Pharmaceuticals during the 2nd quarter valued at about $65,000. Tower Research Capital LLC TRC boosted its holdings in Avadel Pharmaceuticals by 217.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company's stock valued at $78,000 after acquiring an additional 6,025 shares during the period. Exencial Wealth Advisors LLC purchased a new position in Avadel Pharmaceuticals during the 1st quarter valued at about $82,000. Finally, Thoroughbred Financial Services LLC purchased a new position in Avadel Pharmaceuticals during the 1st quarter valued at about $82,000. 69.19% of the stock is currently owned by hedge funds and other institutional investors.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.